Payment overview · 2025
General Payments
$88.25
2 reported records · 2 companies
Healthcare provider profile · identity verified
Vanessa Ho, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIVERSIDE, CA · NPI 1679512776
Verified facts
What the public records show
CMS Open Payments records show Vanessa Ho, MD received $88.25 in general payments during 2025 across 2 reported records.
Avita Medical Americas, LLC accounted for 75.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $66.30 | 75.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.95 | 24.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.25 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $66.30 | 1 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $66.30 | 1 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $66.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1028 | 302 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 222 |
| Losartan Potassium | Losartan Potassium | 537 | 162 |
| Metformin Hcl | Metformin Hcl | 526 | 152 |
| Omeprazole | Omeprazole | 385 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 84 |
| Gabapentin | Gabapentin | 296 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 81 |
| Alendronate Sodium | Alendronate Sodium | 255 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 55 |
| Lisinopril | Lisinopril | 245 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 68 |
| Atenolol | Atenolol | 187 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 182 | 74 |
| Ibuprofen | Ibuprofen | 179 | 62 |
| Carvedilol | Carvedilol | 176 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 51 |
| Glipizide | Glipizide | 157 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 42 |
| Furosemide | Furosemide | 154 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 62 |
| Finasteride | Finasteride | 146 | 48 |
| Naproxen | Naproxen | 144 | 40 |
| Ozempic | Semaglutide | 144 | 30 |
| Januvia | Sitagliptin Phosphate | 136 | 40 |
| Meloxicam | Meloxicam | 134 | 51 |
| Allopurinol | Allopurinol | 127 | 39 |
| Baclofen | Baclofen | 109 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 37 |
| Cephalexin | Cephalexin | 104 | 79 |
| Jardiance | Empagliflozin | 103 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 37 |
| Benazepril Hcl | Benazepril Hcl | 101 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 72 |
| Azithromycin | Azithromycin | 90 | 75 |
| Potassium Chloride | Potassium Chloride | 88 | 34 |
| Arnuity Ellipta | Fluticasone Furoate | 87 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 25 |
| Simvastatin | Simvastatin | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 81 | 25 |
| Donepezil Hcl | Donepezil Hcl | 79 | 20 |
| Eliquis | Apixaban | 79 | 17 |
| Prednisone | Prednisone | 72 | 49 |
| Famotidine | Famotidine | 70 | 23 |
| Meclizine Hcl | Meclizine Hcl | 70 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 16 |
| Sucralfate | Sucralfate | 69 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 69 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 18 |
| Amoxicillin | Amoxicillin | 64 | 49 |
| Metformin Hcl Er | Metformin Hcl | 62 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 52 |
| Topiramate | Topiramate | 59 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 12 |
| Latanoprost | Latanoprost | 56 | 13 |
| Celecoxib | Celecoxib | 52 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 16 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Nystatin | Nystatin | 44 | 29 |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 14 |
| Nitroglycerin | Nitroglycerin | 42 | 20 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Loperamide | Loperamide Hcl | 40 | 19 |
| Nifedipine Er | Nifedipine | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Montelukast Sodium | Montelukast Sodium | 37 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 13 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | 14 |
| Ketoconazole | Ketoconazole | 30 | 12 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 11 |
| Fluocinonide | Fluocinonide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Prolia | Denosumab | 27 | 16 |
| Linzess | Linaclotide | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Entecavir | Entecavir | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | 11 |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.25 · 2 records | Avita Medical Americas, LLC | Cohealyx, Ozempic, Permeaderm, Recell, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error